"I agree with MTB's assessment that the FOB landscape is changing in GTC's favor and Vin's view that FDA approval is a major validation of the platform"
Yes but this market stinks and other opportunities are showing up. Moreover, all what you say will be meaningless by June for GTCB shareholders because LFB will simply devour the company on the cheap at that time...
Nevertheless, GTCB is approaching my buy signal so I may end up joining you once again as a shareholder...:-)
Do any of the diehards have a (set of) criteria in mind that would trigger an exit from the stock?
For example (in order of severity?): ------------------------------------ Stock price below a certain point (down to 20c-ish for example) Further dilutive financing Exit of one or more key employees Closeness to June date for repaying loan More corporate-acquisition news (in or out of the GTCB/LEO/Ovation/Lundbeck universe) More obvious obsfuscation on the part of management Some sort of bad Atryn-related clinical news
Market Data 
Markets 
AI
